First Trust Advisors LP Trims Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

First Trust Advisors LP lessened its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 41.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,169 shares of the company's stock after selling 16,242 shares during the quarter. First Trust Advisors LP owned 0.08% of Krystal Biotech worth $3,630,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. FMR LLC lifted its position in Krystal Biotech by 0.5% in the 4th quarter. FMR LLC now owns 4,314,014 shares of the company's stock valued at $675,833,000 after acquiring an additional 21,133 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Krystal Biotech by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after buying an additional 28,707 shares during the last quarter. Franklin Resources Inc. grew its holdings in Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock worth $43,774,000 after buying an additional 62,178 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Krystal Biotech by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 243,170 shares of the company's stock valued at $38,095,000 after buying an additional 2,954 shares during the last quarter. Finally, Norges Bank bought a new position in Krystal Biotech during the 4th quarter valued at $34,391,000. 86.29% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

KRYS has been the subject of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a report on Tuesday. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Chardan Capital restated a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research note on Wednesday. Guggenheim dropped their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday. Finally, Citigroup boosted their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $218.63.

Krystal Biotech Stock Performance

NASDAQ KRYS traded down $3.79 on Thursday, hitting $133.01. The stock had a trading volume of 79,164 shares, compared to its average volume of 297,458. The firm has a 50-day moving average of $173.11 and a 200-day moving average of $170.64. Krystal Biotech, Inc. has a 52-week low of $132.47 and a 52-week high of $219.34. The company has a market capitalization of $3.84 billion, a price-to-earnings ratio of 44.48 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $88.18 million during the quarter, compared to analysts' expectations of $98.66 million. As a group, research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).